Progressive erosion of β-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes

Diabetes

Volumn 60, Issue 8, 2011, Pages 2086-2091

  Ize Ludlow, Diego ^a,d   Lightfoot, Yaima L ^b   Parker, Matthew ^b   Xue, Song ^b   Wasserfall, Clive ^b   Haller, Michael J ^c   Schatz, Desmond ^c   Becker, Dorothy J ^a   Atkinson, Mark A ^b   Mathews, Clayton E ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL;

ANIMALS; ARGININE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; PREDIABETIC STATE;

EID: 80052827105     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0373     Document Type: Article

References (28)

1. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769
2. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608 (Pubitemid 41007846)
3. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-1920
4. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009;301:1573-1579
5. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
6. Simon G, Parker M, Ramiya V, et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 2008;57:405-414
7. Melanitou E, Devendra D, Liu E, Miao D, Eisenbarth GS. Early and quantal (by litter) expression of insulin autoantibodies in the nonobese diabetic mice predict early diabetes onset. J Immunol 2004;173:6603-6610 (Pubitemid 39541043)
8. Abiru N, Yu L, Miao D, et al. Transient insulin autoantibody expression independent of development of diabetes: comparison of NOD and NOR strains. J Autoimmun 2001;17:1-6 (Pubitemid 32751876)
9. Robles DT, Eisenbarth GS, Dailey NJ, Peterson LB, Wicker LS. Insulin autoantibodies are associated with islet inflammation but not always related to diabetes progression in NOD congenic mice. Diabetes 2003;52:882-886 (Pubitemid 36323599)
10. Kano Y, Kanatsuna T, Nakamura N, et al. Defect of the first-phase insulin secretion to glucose stimulation in the perfused pancreas of the nonobese diabetic (NOD) mouse. Diabetes 1986;35:486-490 (Pubitemid 16078464)
11. Reddy S, Liu W, Thompson JM, Bibby NJ, Elliott RB. First phase insulin release in the non-obese diabetic mouse: correlation with insulitis, beta cell number and autoantibodies. Diabetes Res Clin Pract 1992;17:17-25
12. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 1999;48:989-996 (Pubitemid 29226344)
13. Mathews CE, Graser RT, Savinov A, Serreze DV, Leiter EH. Unusual resistance of ALR/Lt mouse beta cells to autoimmune destruction: role for beta cell-expressed resistance determinants. Proc Natl Acad Sci U S A 2001;98:235-240 (Pubitemid 32095893)
14. Srikanta S, Ganda OP, Gleason RE, Jackson RA, Soeldner JS, Eisenbarth GS. Pre-type I diabetes: linear loss of beta cell response to intravenous glucose. Diabetes 1984;33:717-720 (Pubitemid 14053510)
15. Barker JM, McFann K, Harrison LC, et al. Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing. J Pediatr 2007;150:31-36.e36
16. Srikanta S, Ganda OP, Jackson RA, et al. Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. Ann Intern Med 1983;99:320-326
17. Chaillous L, Rohmer V, Maugendre D, et al. Differential beta-cell response to glucose, glucagon, and arginine during progression to type I (insulin-dependent) diabetes mellitus. Metabolism 1996;45:306-314 (Pubitemid 26102634)
18. Ganda OP, Srikanta S, Brink SJ, et al. Differential sensitivity to beta-cell secretagogues in "early," type I diabetes mellitus. Diabetes 1984;33:516-521
19. Verge CF, Gianani R, Yu L, et al. Late progression to diabetes and evidence for chronic beta-cell autoimmunity in identical twins of patients with type I diabetes. Diabetes 1995;44:1176-1179
20. Trudeau JD, Kelly-Smith C, Verchere CB, et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003;111:217-223 (Pubitemid 36105920)
21. Li L, He Q, Garland A, et al. Beta cell-specific CD4+ T cell clonotypes in peripheral blood and the pancreatic islets are distinct. J Immunol 2009;183:7585-7591
22. André I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A 1996;93:2260-2263 (Pubitemid 26104338)
23. Keskinen P, Korhonen S, Kupila A, et al. First-phase insulin response in young healthy children at genetic and immunological risk for type I diabetes. Diabetologia 2002;45:1639-1648 (Pubitemid 35478133)
24. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS; DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010;59:679-685
25. Kahn SE, Verchere CB, Andrikopoulos S, et al. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 1998;47:640-645 (Pubitemid 28160456)
26. Lo SS, Hawa M, Beer SF, Pyke DA, Leslie RD. Altered islet beta-cell function before the onset of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992;35:277-282
27. Kibirige M, Metcalf B, Renuka R, Wilkin TJ. Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 2003;26:2865-2870 (Pubitemid 37205560)
28. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010;33:826-832